Global Access Strategy & Pricing Franchise Lead mRNA (Secondment 8-9 months)

ROLE SUMMARY

The Vaccine mRNA Franchise Global Access Strategy and Pricing Team Lead Secondee role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance on access pricing optimal reimbursement launch sequencing patient value and evidence generation; she/he is responsible to develop the value and access strategy and its implementation through payer and market insights US Medical International Commercial Office Global Marketing and Policy partnerships.

The mRNA VASP Lead will also spearhead the pipeline strategies for next gen mRNA platform assets (Flu Combo Zoster) and ensure there is robust evidence available for the launch of mRNA Vaccines. The Vaccine mRNA Franchise GASP Team Lead secondee is also responsible for managing a team of 4-plus Global Access and Pricing strategy colleagues focusing on team development/culture and for building a strong partnership across GAV Global cross-functional teams and key prioritized markets.

This team leader will function with a One Pfizer mindset and will lead a cross functional team of health economics and outcomes research (HEOR) scientists real world evidence (RWE) scientists regional H&V International Commercial Office Global Marketing and market access strategists. She/he will lead all mRNA-specific business cases and strategic pricing decisions via the Comirnaty SteerCo and team leader will also become a strategic partner to Global marketing medical and prioritized country teams.

ROLE RESPONSIBILITIES

• Lead Team: Lead the cross functional mRNA/Comirnaty Access Strategy & Pricing matrix team comprised of market access strategists HEOR scientists RWE scientists regional H&V and GLocal colleagues.
• Strategic Partnership: Become an active member of the mRNA Global Marketing extended leadership team and a strategic partner to Global Marketing International Commercial Office US Market Access Medical CSI GPD Corporate Affairs prioritized countries and Regulatory; effectively liaise with GAVs Centers of Excellence.
• Plan & Deliver on Commitments: Orchestrate development of the integrated value and access strategy for all mRNA Assets and implementation of key tactics to maximize access to patients post launch. Enable the execution of outcomes studies and projects Peri and Post launch in alignment with cross-functional colleagues to demonstrate the value proposition for Comirnaty/Flu/Combo to payers and other stakeholders to ensure timely reimbursement expanded and continued access. Lead the Pricing and Access Strategy (via SteerCo/VanTAC) for all mRNA assets to ensure tender success with value-based prices.
• External Partnerships: Develop strategic partnerships and collaborations with key external experts healthcare policy makers HTAs and payers patient advocacy groups and various academic and community settings to support asset strategy.

BASIC QUALIFICATIONS

Candidate demonstrates a breadth of diverse capabilities including: the ability to influence and collaborate with peers develop and coach others oversee and guide the work of external stakeholders to achieve meaningful outcomes and create business impact.

• Bachelors degree minimum required; Masters Degree preferred in a healthcare business or economic field preferred.
• Knowledge and experience in early drug development
• Strong technical knowledge of health economics and pricing/access
• Minimum 12 years experience in health outcomes RWD and / or market access & pricing and related fields.
• Experienced in leading a cross functional team with strong track record of high level of engagement and delivering results
• Skilled in functioning within a matrix organization where managing through influence is required
• In depth understanding of pharmacoeconomics Health-Related Quality of Life and / or pricing and access dynamics required
• Strong methodological skills (study design data analysis and interpretation) in clinical trials epidemiology or health services research preferred
• Experience with HTA organizations such as ACIP NICE SMC PBAC is desirable
• Experience with IDM and EM payers is a must
• Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers; build strategic partnerships internally and externally
• Excellent oral and written English communication skills required
• Strong project management abilities (contracting budgeting vendor management) essential.
• Demonstrated ability to manage multiple projects (multitask) involving complex processes significant budget competing deadlines and rapidly shifting priorities
• Ability to influence key members of scientific and commercial teams constructively and without conflict
• Leadership in studies that involve evidence generation specifically related to RWE NIS studies for access and delivering payer value

Other Job Details:

• Last Date to Apply for Job: June 10th 2025.
• Ability to travel internationally (25%)
• NOT Eligible for Relocation Package

• Note: This secondment offers a valuable opportunity for professional growth. It will need to be funded by the secondees home team

• Secondment 8-9 months
• If you are currently in a driving position with a fleet vehicle and this secondment does not require driving as an essential function of the position for12 months or longer you will be required to turn in your fleet vehicle for the duration of the non-driving secondment. Please refer to the Fleet Policy and Procedures document for more information.

Relocation assistance may be available based on business needs and/or eligibility.